Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Theralase Technologies ( (TSE:TLT) ) has issued an announcement.
Ferring Pharmaceuticals and Theralase Technologies have signed a clinical development agreement to test a combination therapy using Ferring’s FDA-approved intravesical gene therapy ADSTILADRIN and Theralase’s investigational light-activated small molecule Ruvidar in patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ, with or without papillary tumors. Theralase will remain the study sponsor under its ongoing Study II program, adding a new cohort in the United States that may expand to Canada or other countries, with both companies jointly overseeing development; the collaboration aims to enhance efficacy and durability of response by combining two complementary mechanisms of action and could strengthen Theralase’s clinical and regulatory trajectory for Ruvidar while reinforcing Ferring’s ambition to position ADSTILADRIN as a backbone therapy in this evolving treatment landscape.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and significant equity depletion—despite modest leverage. Technicals are supportive (price above key moving averages with a positive MACD) but look overbought (high RSI/Stoch), and valuation is constrained by a negative P/E that reflects continued unprofitability.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a medical technology company focused on developing light-activated small molecule therapeutics for oncology, with a particular emphasis on non-muscle invasive bladder cancer. Its lead investigational product, Ruvidar (TLD-1433), is designed to penetrate cancer cells and, upon light activation, deliver targeted cytotoxic effects while inducing immunogenic cell death to stimulate both innate and adaptive immune responses.
Average Trading Volume: 164,688
Technical Sentiment Signal: Hold
Current Market Cap: C$50.13M
Learn more about TLT stock on TipRanks’ Stock Analysis page.